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Imprinting centers (IC) can be defined as cis-elements that are recognized in the germ line and are epigenetically modified to bring about the
full imprinting program in a somatic cell. Two paternally expressed human genes, HYMAI and PLAGL1 (LOT1/ZAC), are located within human
chromosome 6q24. Within this region lies a 1-kb CpG island that is differentially methylated in somatic cells, unmethylated in sperm, and
methylated in mature oocytes in mice, characteristic features of an IC. Loss of methylation of the homologous region in humans is observed in
patients with transient neonatal diabetes mellitus and hypermethylation is associated with a variety of cancers, suggesting that this region
regulates the expression of one or more key genes in this region involved in these diseases. We now report that a transgene carrying the human
HYMAI/PLAGL1 DMR was methylated in the correct parent-origin-specific manner in mice and this was sufficient to confer imprinted
expression from the transgene. Therefore, we propose that this DMR functions as the IC for the HYMAI/PLAGL1 domain.
© 2006 Elsevier Inc. All rights reserved.Keywords: Genomic imprinting; DNA methylation; Imprint control region; HYMAI/PLAGL1Imprinting is a non-Mendelian form of inheritance in which
only one of the two inherited alleles is expressed. This is
dependent on differential epigenetic marking of the two
parental alleles in the germ line [1–4]. The differential
expression of imprinted genes accounts for the requirement
for both maternal and paternal genomes in normal develop-
ment [5,6]. Many imprinted genes play significant roles in
regulating embryo growth, placental function, and neurobeha-
vioral processes (summarized in http://www.mgu.har.mrc.ac.
uk/research/imprinting/function.html). Studies of a number of
chromosomal domains have demonstrated that imprinted genes
are predominantly located in clusters, where they exhibit a
complex sharing of control elements [7–9]. This regulation⁎ Corresponding author. Fax: +81 957 271661.
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doi:10.1016/j.ygeno.2006.07.005appears to be mediated by imprinting centers (IC). IC are
responsible for the establishment of differential imprinted
genomic marks in the germ line, the maintenance of these
marks through development, and the ultimate execution of
differential expression programs for the two parental alleles
[10]. The most likely candidate for the gametic mark that
distinguishes the parental alleles is DNA methylation [1].
DNA methylation is a both heritable and reversible epigenetic
modification that is stably propagated after DNA replication
and influences gene expression [11]. Allele-specific DNA
methylation has been observed within all well-characterized
imprinted domains. In some instances, the methylation is
present at the promoter of the inactive gene, suggesting a
direct role for DNA methylation in silencing of the gene.
We previously identified the human imprinted region at
chromosome 6q24, syntenic to mouse chromosome 10A, in a
651T. Arima et al. / Genomics 88 (2006) 650–658screen for imprinted genes [12,13]. Two paternally expressed
human genes are located in this domain, HYMAI and PLAGL1
(LOT1/ZAC) [12,14,15]. HYMAI generates an untranslated
mRNA of unknown function, while PLAGL1 encodes a zinc
finger protein that localizes to the nuclear compartment and
functions as a transcription factor [16]. We showed that a CpGFig. 1. Generation and methylation analysis of the human HYMAI/PLAGL1 DMR
(938 bp) region and pIRES-eGFP expression vector (5.3 kb) (Clontech). The human
site) and exon 1 of HYMAI. PCR primers for bisulfate-treated genomic DNA of the hu
were analyzed (the vertical bars). The restriction sites are BamHI (B), XhoI (X), SmaI
subjected to Southern blotting. The DNA was digested with BamHI and XhoI and t
DMR probe. Bottom: Methylation status of the human HYMAI/PLAGL1 DMR in li
methylation profile within the pool of clones sequenced. Each circle within a row re
methylated cytosines). (C) Genomic DNA from the tails of six F2 transgenic animals
line 12 (from paternal transmission) was subjected to Southern blotting. The DNA
individuals inheriting the transgenes from either a male or a female from line 12 o
unmethylated patterns. C, control DNA (12-4-1) digested with BamHI and XhoI wit
transgenic human HYMAI/PLAGL1 DMR by bisulfite PCR methylation assay in F3 e
clones are shown. Black circles indicate methylation; white circles represent unm
transmission are methylated in the transgenic human DMR. In contrast, the clones aisland overlapping exon 1 of PLAGL1/HYMAI is differentially
methylated in somatic cells [17]. The region is unmethylated in
sperm but methylated in growing oocytes, a difference that
persists between parental alleles throughout pre-and postim-
plantation development. A region within this differentially
methylated CpG island exhibits a high degree of homologytransgenic mice. (A) Structure of the transgene human HYMAI/PLAGL1 DMR
HYMAI/PLAGL1 DMR includes a promoter (at −477 on the transcriptional start
man DMR are indicated. 17 CpG sites within the humanHYMAI/PLAGL1 DMR
(S), and NotI (N). (B) Genomic DNA from the tails of F1 transgenic animals was
he methylation-sensitive restriction enzyme NotI and hybridized with a human
nes 12 and 21 analyzed by bisulfite sequencing. Each row represents a unique
presents a single CpG site (open circles, unmethylated cytosines; filled circles,
from line 68 (from maternal transmission) and seven F2 transgenic animals from
was digested as described for (B). (D) Southern analysis of DNA from F3
r 68. Both lines show the maternal-specific methylation and paternal-specific
hout the methylation-sensitive restriction enzyme NotI. Bottom: Analysis of the
mbryos after paternal or maternal transmission for line 12. Individual sequenced
ethylated residues in individual clones. The sequenced clones after maternal
fter paternal transmission are almost all unmethylated.
Fig. 1 (continued).
652 T. Arima et al. / Genomics 88 (2006) 650–658between mouse and human [17,18]. We and others have
recently shown that acquisition of oocyte methylation at the
mouse Hymai/Plagl1 CpG island is completed in early growing
oocytes at the same time as the primary imprinting of Plagl1
expression [19,20]. These features led us to suggest that this
CpG island marks the position of the IC for this domain.Evidence supporting a role for this CpG island in
regulating gene expression comes from studies on human
cancers. Hypermethylation of this region leading to
transcriptional silencing of PLAGL1 has been reported in a
variety of human cancers, including ovarian cancer [21,22].
Furthermore, patients with transient neonatal diabetes
Table 1
Methylation profiles of human HYMAI/PLAGL1 DMR F1 transgenic mice
Line Copy number % methylation
Female founder 8 6 92.7
12 22 89.4
17 20 63.5
25 18 83.5
49 20 56.5
29 16 87.1
14 5 21.2
Male founder 21 6 15.3
55 4 15.9
62 18 20.0
81 16 13.5
68 6 13.5
69 3 11.6
The copy number and methylation pattern of the human HYMAI/PLAGL1 DMR
transgene for paternal and maternal transmission from founder animals are
shown. % methylation of the human HYMAI/PLAGL1 DMR was obtained by
bisulfite-PCR sequencing.
653T. Arima et al. / Genomics 88 (2006) 650–658mellitus consistently show loss of methylation at this CpG
island [23].
Previously, IC have been defined by genetic analysis using
deletions to map the elements that may be necessary for this
process or by using transgenes in mice to determine the minimal
sequence information sufficient to carry out the full imprinting
program [24–41]. There is evidence that an IC lies within a 175-
kb region spanning the human PLAGL1/HYMAI locus since a
PAC clone carrying this sequence is apparently able to direct
imprinted expression of PLAGL1 in mice [42]. In this study, we
examined the imprinting capabilities of a much smaller region,
the human HYMAI/PLAGL1 differentially methylated CpG
island, in transgenic mice. We found that the human HYMAI/
PLAGL1 CpG island can acquire parental-origin-specific
methylation in the maternal germ line and that this modulates
expression of a linked reporter. This supports our hypothesis
that this CpG island is the IC for the HYMAI/PLAGL1 imprinted
domain.
Results
Production of transgenic mice
To test whether the human HYMAI/PLAGL1 DMR might
be sufficient to promote a parent-origin-specific methylation
pattern and imprinted expression in the mouse, we
constructed a human HYMAI/PLAGL1 DMR reporter
transgene by cloning the DMR into the pIRES-eGFP vector
(Fig. 1A). We generated 28 founder animals by pronuclear
injection, which were initially identified in a PCR screen
(28/200). To determine the copy number of the integrated
transgenes, we performed Southern blotting using the same
amount of DNA in human placenta and compared it to the
density of the band using the densitometer (Table 1). We
then crossed transgenic founders with the wild-type C57BL/
6J mice to establish independent lines. We obtained germ-
line transmission of the transgene in 13 independent lines, 6
lines from male founders and 7 lines from female founders.
We also made transgenic mice with only the pIRES-eGFP
vector as a control.
Allele-specific methylation of the human HYMAI/PLAGL1
DMR in transgenic mice
The endogenous human HYMAI/PLAGL1 DMR has a
maternal-origin-specific methylation pattern [17,19]. We exam-
ined the methylation pattern of the transgene inherited from the
male and female founders in F1 individuals. Tail DNA from
one transgenic F1 animal was analyzed for each line. DNAwas
digested with XhoI and BamHI and the methylation-sensitive
restriction enzymes NotI and/or SmaI. We performed Southern
blot using the human HYMAI/PLAGL1 DMR probe (shown in
Fig. 1A). We found that the six lines for which the founder was
male showed the unmethylated pattern as would be predicted
for paternal inheritance of this DMR. Six of the lines for which
the founder was female showed either full or partial methyla-
tion, again consistent with this region acquiring the germ-line-appropriate mark, and 1 line demonstrated the unmethylated
pattern (Fig. 1B). These results were confirmed by bisulfite
analysis. After bisulfite treatment of the DNA samples, the
human HYMAI/PLAGL1 DMR was amplified by PCR,
fragments were subcloned and sequenced, and methylation
status was determined at the 17 CpG sites of the human HY-
MAI/PLAGL1 DMR. Results are shown in Fig. 1B and Table 1
and were consistent with the data obtained by Southern
blotting.
For an IC to function, not only must the epigenetic mark be
made in the appropriate germ line but also it must be erased
so that the appropriate, sex-specific mark can be reestablished
for the next generation and to switch back and forth from the
male to the female imprint. We therefore chose to examine the
ability of our transgene to switch imprint in line 68, whose
founder was originally male, and in line 12, whose founder
was female. For line 68, we found that the F1 female, who
had inherited an unmethylated DMR from her male parent,
passed on a methylated DMR to all six of her offspring (Fig.
1C). Therefore in this line, the imprint switched from
unmethylated (male) to methylated (female). For line 12, the
male F1 animal that had inherited a methylated DMR from his
female parent passed on an unmethylated DMR to six of his
offspring, again showing appropriate switching. Lines 8, 21,
25, 29, 55, 62, 69, and 81 showed similar switching (data not
shown).
Finally, we examined whether the methylation imprint
persisted. We examined methylation after both paternal and
maternal transmission in the F2 generation by Southern
blotting and bisulfite-modified genomic sequencing (Fig.
1D). The appropriate switch was again observed.
DNA methylation of the human HYMAI/PLAGL1 DMR
modulates expression of the linked reporter
DNA methylation influences gene expression. In some
instances, the methylation is present on the inactive gene,
suggesting a role for DNA methylation in silencing of the
654 T. Arima et al. / Genomics 88 (2006) 650–658gene. We therefore examined whether the methylation status of
the transgene had an affect on eGFP reporter gene expression.
We performed Northern blotting of the mRNA from F3
neonate liver after male or female transmission for line 12 and
line 68 (Fig. 2A). For line 12, we found that the eGFP mRNA
was expressed more highly after paternal transmission
(unmethylated transgene) than after maternal transmission
(methylated transgenes). Some expression from the methylated
transgene was detectable, which suggests that the DNA
methylation was not able to suppress all transcription
completely. This may be because the hybrid sequence is not
able to respond exactly as an imprinted gene or perhaps be due
to copy number. Nonetheless, there is still a distinct difference
in the level of expression after maternal and paternal
transmission suggesting that this DNA region can act to
regulate allele-specific gene expression. A similar pattern was
obtained for line 68 (Fig. 2A).
Next, we analyzed whether appropriate allele-specific
expression from the transgene was also present in the placenta
and whether it persisted in adult tissues. Expression of eGFP
was detected strongly in brain, kidney, and placenta after male
transmission (Fig. 2B), with weaker expression in the liver,
lung, and spleen. After female transmission, a similar but much
lower level of expression was observed in these tissues,Fig. 2. Methylation of the transgenic human HYMAI/PLAGL1 DMR suppresses expr
neonate liver carrying the maternally inherited (lanes 12-1-1, 12-1-2, 12-1-4) and pate
with eGFP and Gapdh cDNAs. There is high expression of eGFP after paternal tra
shown under the lanes (eGFP/Gapdh ratio). (B) eGFP expression in adult brain, liv
paternal transgene (right). Gene expression was quantified on the BAS 2000 systemdemonstrating that the imprint-linked expression was preserved
into adulthood and in extraembryonic tissues (Fig. 2B).
Silencing of the HYMAI/PLAGL1 DMR transgene in the
nongrowing oocytes
The establishment of methylation imprints proceeds in a
gene-specific manner while oocytes are arrested at prophase I
and transitioned from primordial to antral follicle [43–45]. We
previously reported that the acquisition of the methylation
imprint of the mouse Hymai/Plagl1 DMR begins around 5 days
postpartum (dpp) in the early nongrowing oocyte and the
primary imprinting of Plagl1 is completed during the 5-to 10-
dpp oocyte growth phase [20]. We examined whether imprint-
ing of our transgene followed this time scale. eGFP expression
was determined in 5-, 10-, and 15-dpp ovaries from juvenile
mice using immunofluorescence microscopy (Fig. 3). Almost
all oocytes from the primordial follicle in 5-dpp ovaries showed
strong expression of eGFP (percentage of highly expressed
oocytes, 82.8%, 92/111 (n=5)). However, the 10-dpp early
growing oocytes showed a mixture of high expression (45.7%,
32/70 (n=5)) and low expression (38.5%, 27/70 (n=5)).
Almost all of the germ cells from 15-dpp oocytes derived
from early antral follicles showed no expression of eGFPession of a linked reporter. (A) Northern bolt analysis of RNA isolated from F3
rnally inherited (lanes 12-4-1, 12-4-2, 12-4-3) transgene hybridized sequentially
nsmission but not after maternal transmission. The relative intensity (eGFP) is
er, lung, spleen, placenta, and kidney. Maternally inherited transgene (left) and
(Fuji Film) and normalized for the total RNA by rehybridizing with Gapdh.
Fig. 3. The timing of imprinting of the human HYMAI/PLAGL1 DMR during postnatal oocyte growth. eGFP expression was examined by immunofluorescence
microscopy analysis in oocytes at different stages of development. Scale bar, 300 μm. (A) Low-(left image) and high-(middle image) magnification H+E section of
5-dpp ovary is shown with black arrow indicating sample primordial follicle stage oocyte. Image on right shows eGFP signal obtained from this follicle. (B) Low-
(left image) and high-(middle image) magnification H+E section of 10-dpp ovary in which there is a mixture of oocytes with low expression of eGFP (shown in
right-hand image, top row) and high expression (right-hand image, bottom row). (C) Low-(left image) and high-(middle image) magnification H+E section of 15-
dpp ovary. Early antral follicle stage oocyte (right image) shows low expression of eGFP.
655T. Arima et al. / Genomics 88 (2006) 650–658(12.2%, 4/33 (n=5)). These data suggest that the human DMR
acquires the maternal silencing imprint during the 5-to 10-dpp
oocyte growth stage in a fashion similar to that of the mouse
DMR.
In conclusion, we have shown that a 936-bp region of the
human PLAGL1 DMR can be recognized by the imprinting
machinery of the mouse germ line and correctly methylated in
the female germ line at the time point at which the endogenous
mouse DMR is known to acquire an imprint. Furthermore, theDNA methylation is able, at least in part, to silence expression
of a linked reporter gene on our construct, suggesting that this
sequence forms part of the IC from the human HYMAI/PLAGL1
imprinted domain.
Discussion
Despite the apparent conservation of imprinting among
mammals, there are few examples of human transgenes
656 T. Arima et al. / Genomics 88 (2006) 650–658imprinting appropriately in mice [38,39,46–48]. Furthermore,
there are few data available to show that small regions can
reliably direct imprinting on transgenes, thus making the precise
dissection of these regions quite challenging. Here we have
shown that a small (936 bp) region from the human HYMAI/
PLAGL1 DMR can acquire the appropriate maternal-specific
methylation in the mouse germ line and that this robust
methylation imprint can switch back and forth between the
germ lines for three generations (Fig. 4). This region was
previously shown to contain maternal-specific methylation in
humans [12,14] as well as in mice [17]. This demonstrates first
that, at least for this DMR, there is no species barrier between
human and mouse in the imprinting mechanism. In contrast,
imprint acquisition of human H19 DMR does not appear to be
conserved in transgenic mice [38]. Although we cannot exclude
the possibility that the human DMR acts only in the context of
the IRES-eGFP transgene, this work provides further evidence
that this region is the major IC for the HYMAI/PLAGL1 domain.
The basic principles that govern the establishment and
maintenance of domain-wide imprinted gene expression
patterns have been elucidated in a general manner and seem
to be mediated at the molecular level by DMRs. The order of
events and all the players are still to be elucidated. Our
findings will make this process easier as we can focus all our
efforts on a much smaller region, identifying proteins that
bind to this sequence in extracts from different material, such
as mouse oocytes, at different stages of development and
establishment of the imprint. Having defined an IC within a
936-bp sequence, we can now proceed to analyze this regionFig. 4. Family tree of transgenic lines showing switch from maternal to paternal to mbase by base to identify the sequence motif recognized in the
female germ line that establishes DNA methylation or,
conversely, a sequence motif that blocks DNA methylation
in the male germ line.
Materials and methods
Production and analysis of human HYMAI/PLAGL1 DMR transgenic
mice
The eGFP-tagged HYMAI/PLAGL1 DMR mammalian expression vector
was constructed by cloning a 936-bp fragment spanning the human HYMAI/
PLAGL1 DMR into the XhoI and BamHI sites upstream of the IRES of the
pIRES-eGFP vector (Clontech, Palo Alto, CA, USA). DNAwas purified using a
midiprep kit (Qiagen, Tokyo, Japan) and linearized by XhoI digestion prior to
microinjection into F1 (C57BL/6J×CBA) embryos. Embryos were then
transferred to C57BL/6J pseudopregnant females, all according to standard
procedures [49]. Genomic DNA was isolated from the tail biopsy of newborn
mice as described previously [14]. The transgenic event was initially examined
using two kinds of PCR to detect the human HYMAI/PLAGL1 DMR and the
eGFP fragment, respectively. Primers used for the HYMAI/PLAGL1 DMR
were 5″-AGTATGTCTGATACAGTCTG-3″ and 5″-TTTGCGCGCCGCC-
TACGTG-3″ and for eGFP were 5″-CGCACCATCTTCTTCAAGGACG-3″
and 5″-TGCTCAGGTAGTGGTTGTCG-3′. The amplification consisted of a
total of 30 cycles at 95°C for 30 s, 65°C for 30 s, and 72°C for 30 s in a Perkin–
Elmer GeneAmp PCR System 2400. After PCR screening, we performed
Southern blotting to determine the copy number of the transgenic integrations by
comparison with a known quantity of human placental genomic DNA. Genomic
DNAs (5 μg) were digested with XhoI and BamHI. Filters were probed with a
[32P]dCTP-labeled 936-bp HYMAI/PLAGL1 DMR fragment. Hybridization
signals were analyzed using a Fuji Phosphoimager and on Kodak film (Tokyo,
Japan). Twenty-eight transgenic animals were identified. Subsequently,
founders were crossed with wild-type C57BL/6J mice to generate 13aternal imprint in line 12 and from paternal to maternal to paternal in line 68.
657T. Arima et al. / Genomics 88 (2006) 650–658independent transgenic lines. All further analysis was performed on the C57BL/
6J strain background.
Methylation analysis
Genomic DNAs of the transgenic mice were digested with XhoI and BamHI
and a methylation-sensitive endonuclease, NotI and/or SmaI, followed by
electrophoresis on 1% agarose gels. Southern blots were performed using a 936-
bp fragment from the human HYMAI/PLAGL1 DMR.
Bisulfite treatment was carried using the EZ DNA methylation kit (Zymo
Research, CA, USA) according to the manufacturer's instructions. Different
samples of bisulfite-treated DNA were amplified by single PCR of the human
DMR. The primer sequences and PCR conditions for the HYMAI/PLAGL1
DMR were as described previously [19]. The amplified fragments were cloned
into the TOPO TAvector (Invitrogen, Tokyo, Japan) and individual clones were
sequenced using a T7 primer and/or M13 reverse primer.
Northern blot analysis
Total RNA was isolated from neonate liver and adult organs using Isogen
(Nippon Gene, Tokyo, Japan). Northern blot analysis was carried out as
previously described [17]. eGFP cDNA (321 bp; pIRES2-eGFP vector 1542–
1863) was used as a probe. Gene expression was quantified on the BAS 2000
system (Fuji Film) and normalized for total RNA by rehybridizing with Gapdh
(Clontech). The relative intensity of eGFP is presented as an eGFP/Gapdh ratio.
GFP analysis
Sections were observed by immunofluorescence microscopy (LSM510-
META, Zeiss, Germany, and SZY9, Olympus, Japan). The ovaries of F3
transgenicmice at 5, 10, and 15 dppwere used in the analysis of eGFP expression
in their oocytes.Acknowledgments
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